HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Thieblemont, C. Search for Related Content PubMed PubMed Citation Articles by Thieblemont, C. Social Bookmarking                   What's this?

Clinical Presentation and Management of Marginal Zone Lymphomas

Correspondence: Catherine Thieblemont, MD, PhD, Centre Hospitalier Lyon-Sud, Pavillon 1F, Pierre-Benite 69310, France; Phone: +33 (0)4 78864305, Fax: +33 (0)4 78864354, catherine.thieblemont{at}chu-lyon.fr

Abstract

Marginal-zone lymphoma (MZL) includes three subtypes depending on the site of lymphoma involvement: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma); splenic MZL; and nodal MZL. Beside a common cell-of-origin and similarities concerning a possible chronic antigenic stimulation by microbial pathogens and/or autoantigens, the clinical presentation is very different with symptoms related to lymphoma location. MALT and splenic MZL present with an indolent disease with good performance status, no B symptoms, and no adverse prognostic factors and are associated with long survival. Patients with nodal MZL present with a more aggressive disease and have a shorter failure-free survival. Clinical and biological prognostic factors identified in reported series are heterogeneous. The optimal treatment has yet to be defined for the three subtypes, and current strategies will be described in this review.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?